Abstract
Purpose: To investigate the combined effect of dydrogesterone and letrozole on humoral immunity, and levels of sex hormones and serology-related indices in patients with endometriosis.Methods: Patients with endometriosis (98 cases) were randomly assigned to two groups of 49 patients each: control group and study group. The control group received dydrogesterone (10 mg/kg) orally from the fifth day to the twenty-fifth day of the patient's menstrual cycle, twice daily; while the study group, in addition to dydrogesterone (10 mg/kg), received letrozole (2.5 mg/kg). Treatment in both groups lasted one month, and changes in the levels of humoral immunity, sex hormones and serology-related indices were evaluated before and after treatment. Clinical effectiveness and adverse reactions in both groups were also assessed.Results: After treatment, total effectiveness was markedly higher in the study group (91.84 %) than in control group (77.55 %, p < 0.05). Post-treatment, humoral immunity (IgM, IgG and C3) levels were significantly higher in the study group than in control group (p < 0.05) while estradiol (E2) level in both groups were significantly reduced; however, E2 level was markedly lower in the study group than in control group (p < 0.05).Conclusion: These results suggest that the combination of dydrogesterone with letrozole alleviates clinical symptoms of endometriosis, improves humoral immune function, and maintains sex hormone levels.Keywords: Endometriosis, Dydrogesterone, Letrozole, Humoral immunity, Sex hormones, Serologicalrelated indices
Highlights
Endometriosis is a medical condition in women caused by the growth of endometrial tissue outside the uterine cavity
The aim of this study was to investigate the influence of combination of dydrogesterone and letrozole on humoral immune function, levels of sex hormones and serology-related indices in patients with endometriosis
Study group post-treatment levels of Immunoglobulin M (IgM), Immunoglobulin G (IgG) and C3 were significantly higher than the corresponding control values (p < 0.05)
Summary
Endometriosis is a medical condition in women caused by the growth of endometrial tissue outside the uterine cavity. Women of childbearing age are at increased risk of this disease which manifests mainly as dysmenorrhea, dyspareunia, chronic pelvic pain, attachments, and infertility [1, 2]. Surgery and use of drugs are the major treatment options for endometriosis. Dydrogesterone prevents intimal hyperplasia and carcinogenesis caused by estrogens [3], while letrozole inhibits the synthesis of estrogen and increases the secretion of gonadotropin in a bid to promote rapid development of follicles [4]. The aim of this study was to investigate the influence of combination of dydrogesterone and letrozole on humoral immune function, levels of sex hormones and serology-related indices in patients with endometriosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
